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Abstract

The purpose of this quality improvement project was to implement the standardized use
of Bioimpedance Spectroscopy (BIS) for the early detection and management of breast cancerrelated lymphedema (BCRL). BCRL is a common complication of breast cancer treatments
resulting from damage to the lymphatic system. While three of every four patients that develop
lymphedema typically do so within the first three years after treatment, this complication can
develop at any time during or after therapeutic intervention. The National Comprehensive
Cancer Network® Clinical Practice Guidelines and others suggest that bilateral baseline limb
measurements should be performed on patients at high risk for developing post-treatment BCRL.
Early detection and diagnosis of lymphedema are critical for its optimal management because
while stages 0 and 1 are reversible, stages 2 and 3 are typically less responsive to treatment.
Subclinical BCRL can be detected using BIS before, during, and after surgical procedures and
chemoradiation therapy. Furthermore, this procedure can be repeated at regular intervals to
monitor lymphedema. This QI project identified changes and improvements in which the use of
BIS resulted in superior outcomes for breast cancer patients. One hundred and thirty-one charts
were reviewed, and five participants were included in the QI project. The types of breast cancer
ranged from Stage 1A, invasive ductal carcinoma (IDCA), hormone receptor positive, sentinel
axillary lymph node biopsy (SLNB), axillary lymph node dissection (ALND), Stage 3B, and
Stage 3A, triple negative receptor. BIS is an important modality that can be used to evaluate the
effectiveness of clinical interventions and to manage pivotal outcomes in patients with BCRL.
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Prophylactic Bioimpedance Spectroscopy for Breast Cancer-Related Lymphedema

Background Knowledge
As part of this Quality Improvement (QI) project, I identified an opportunity to improve
clinical outcomes for breast cancer patients undergoing outpatient treatment at our center. Breast
cancer-related lymphedema (BCRL) is a common complication of breast cancer treatment that
results from damage to the lymphatic system. Lymphedema can be acute or chronic (NCCN
Guidelines, 2021). While three of every four patients who ultimately develop lymphedema
typically present within the first three years after treatment, this complication can develop at any
time during or after therapeutic intervention. A recent study published in the Annals of Surgical
Oncology reported that BCRL represents a significant source of lifelong morbidity among breast
cancer survivors (Ridner, et al., 2019). In the United States alone, the annual cost of cancerrelated lymphedema has been estimated at $7 billion. The costs of healthcare for breast cancer
survivors who develop lymphedema within two years following cancer treatment have been
estimated to be $120,00 higher than costs for those who remained free of this complication.
These estimated costs included 112% higher annual out-of-pocket expenses and $3,325
additional costs per year due to loss of productivity (Dean, et al., 2019).
The use of Bioimpedance Spectroscopy (BIS) can facilitate subclinical detection and
early intervention and thus a 95% reduction in the progression of lymphedema. BIS uses an
electrical current to detect volume of extracellular fluid that is converted into a lymphedema
index score (L-Dex) measurement with increased validity and sensitivity when compared to
traditional modalities such as circumference measurements as well as having the ability to detect
subclinical or stage 0 BCRL (Shah, et al., 2016). My Doctor of Nursing Practice (DNP) QI
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project was designed to address early detection of BCRL using BIS as a critical change that
might improve healthcare outcomes for my breast cancer patients. My practice setting includes
patients 20 to 80 years of age diagnosed with breast cancer, including those who are pre- and
post-treatment with chemoradiation therapy and surgery. This cohort includes patients at highrisk for developing lymphedema because of extensive axillary lymph node dissection (ALND)
and/or sentinel lymph node biopsy (SNLB). These patients include those who have and have not
been treated, radiation and/or taxane-based chemotherapy. My clinical cohort includes patients
of all socioeconomic backgrounds and those who are primarily Spanish or English speaking.
As part of my 10-day reflective practice log, I performed a clinical needs assessment of
my practice, reflected on my findings, and identified an opportunity to improve the care I
currently provide to my patients. I learned that I was not taking a sufficiently proactive approach
to the early detection and prevention of acute and chronic BCRL. Furthermore, I surveyed the 10
providers in my clinic and discovered lymphedema was routinely assessed by physical
examination rather than by the methods suggested by the National Comprehensive Cancer
Network® (NCCN) guidelines (i.e., version 3.2021 Survivorship: Lymphedema Principles).
Among other principles, these guidelines suggest that pretreatment bilateral limb measurements
should be performed on all patients to provide a baseline for survivors who might be at risk for
developing treatment-related lymphedema. Early detection and diagnosis are critical for optimal
management of this condition. Lymphedema diagnosed at stages 0 and 1 is frequently reversible,
whereas stages 2 and 3 are typically less responsive to treatment (National Comprehensive
Cancer Network, 2021). My current practice does not include an opportunity to prevent stage 0,
subclinical lymphedema. Treatment is initiated at stage 1 when pitting edema is evident. My
research suggested that BIS could be used to facilitate this type of evaluation, as it can be
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performed before, during, and after breast surgery and chemoradiation therapy. BIS can be
repeated at regular intervals (e. g., every three months) to monitor the development of
lymphedema and the results of these studies can be used to direct therapeutic intervention and
appropriate management.
Local Problem
The local problem addressed in this project is early diagnosis and treatment of
lymphedema. My review of the pertinent literature suggested that BIS may be a valuable
screening tool that can be used to facilitate early diagnosis and intervention, thus improving our
chances of eliminating BCRL before it progresses to an irreversible state (Ridner, et al., 2022).
Intended Improvement
The changes and improvements made in addressing the processes and outcomes of the
proposed intervention were overall positive. The process began with establishing rapport with
the patient and her family at the initial encounter. Patients were provided with evidence-based
literature which typically empowered and motivated them to take a proactive approach to their
care. My ability to monitor subclinical BCRL via the use of BIS facilitates early intervention and
significantly reduces the risk of chronic disease compared to monitoring efforts based on arm
circumference determined by tape measure alone. Thus, BIS should be considered and available
for screening for subclinical BCRL, especially for patients in high-risk populations (Shah, et al.,
2021). According to the Institutional Review Board (IRB) application (discussed below), five
patients met the criteria for enrollment. Inclusion criteria for the QI project are patients 20 to 80
years of age diagnosed with breast cancer, pre-treatment, post chemoradiation therapy, and postsurgical. The exclusion criteria were patients not meeting inclusionary criteria.
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The Medical Director of our clinic and my collaborating physician were champions of
this work and the intended QI that might result from the intervention proposed. We all agreed
that this would be an excellent time to reconsider our current underutilization of BIS and to make
appropriate changes to our clinical practice.
Methods
Ethical Issues
I completed the Collaborative Institutional Training Initiative (CITI) training course that
was intended to foster ethical integrity when conducting a QI study. Ethical considerations for a
QI project included a process for attaining IRB approval. The IRB process was completed
through the IRBnet website, https://www.irbnet.org/release/home.html. The application was
submitted to The University of Texas at El Paso IRB Office of the Vice President for Research
and Sponsored Projects. The University of Texas at El Paso IRB determined that this QI project
did not meet the definition of human subjects research under the purview of the IRB federal
regulations and granted approval.
Setting
Elements and characteristics of the setting that were most likely to benefit from a change
and/or improvement in my clinical practice are breast cancer survivors at risk for BCRL. My
practice includes patients 20 to 80 years of age who have been diagnosed with breast cancer who
are currently in pretreatment, active treatment with chemotherapy/radiation, or post-surgery
phases. Monitoring with BIS will have the most impact on this patient cohort as current evidence
suggests that early detection and intervention can significantly reduce the risk of developing
chronic BCRL by 69% and 81% compared to that achieved by routine evaluation and
measurements alone, particularly in high-risk patients (Shah, et al., 2021).
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Planning the Intervention
The Texas Advanced Practice Registered Nurse scope of practice and the American
Academy of Nurse Practitioners National Certification Board, which both protect public health
by overseeing and ensuring safe nursing practices, permitted me to introduce BIS technology to
better serve my patients. This problem was reviewed and documented in great detail during a
ten-day reflective period. I reflected on every step of the advanced practice process used to care
for breast cancer patients who were at risk for developing BCRL and looked for new areas of
opportunity. My patient cohort included a large number of breast cancer survivors who had
undergone lumpectomy, SLNB, ALND, active adjuvant taxane-based chemotherapy,
neoadjuvant chemotherapy, and/or adjuvant radiation. As noted in the NCCN guidelines (version
3.2021), BCRL has emerged as an important clinical issue due to the frequency of treatmentrelated injury to the lymphatic system. For example, during my ten-day reflective period, I
encountered one breast cancer survivor with severe, irreversible lymphedema (stage 3). It
became apparent that I needed to take a more aggressive approach to early detection and
prevention of BCRL with baseline measurements before and after treatment.
Before initiating this intervention, I trained myself on how to operate the BIS device,
including preparation, performing the evaluation, viewing the measurements, and documenting
the results. A self-test was performed before each patient trial to ensure that the device was
functioning properly. BIS is an advanced modality in which bioimpedance measurements are
used to assess fluid levels and tissue composition. This is achieved by sending a painless
alternating electrical current through the patient’s body. Impedance is a measure of the
opposition to electrical flow measured in ohms that represents a combination of both resistance
and reactance (i.e., factors that oppose the alternating current; ImpediMed, 2014). The outcome
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of BIS is presented as a Lymphedema index score (L-Dex). BIS is a rapid, noninvasive, and costeffective technique designed to aid clinical assessment by monitoring fluid content, in this case
in the patient’s arm. This modality is approximately four times more sensitive than any of the
other commonly used methods for assessing lymphedema. The BIS device includes a tetrapolar
set of leads that are attached to electrodes that adhere to the skin and measure current, voltage,
and phase angle. These variables are then used to calculate the three critical bioimpedance
parameters: impedance (Z), resistance (R), and reactance (Xc). These calculations are used to
estimate impedance over a frequency range of 4–1000 kHz to generate a value defined as true
bioimpedance (ImpediMed, 2014).
Finally, as part of my overall reflection on this issue, I reviewed the electronic charts in
the outpatient cancer treatment center and became aware of the current practice standards. This
action was the catalyst that influenced my decision to pursue this QI project to improve my
approach to lymphedema screening and prevention.
Review of Patients and Development a of PICOT question
The review of patient data was recorded for 10 days of practice and was organized by the
nursing process that includes assessment, diagnosis, treatment/intervention, and follow-up. A
PICOT (patient, intervention, current practice, outcome, and time) question was generated based
on my identification of the major diagnosis associated with recurrent complaints and ineffective
interventions. Specifically, I studied and reviewed patient diagnoses of chronic lymphedema and
assessed what interventions might be implemented during the acute phases of this condition. My
findings were similar to those of Disipio et al., (2013) who reported the need for an improved
understanding of the prevention and management strategies that might be used to reduce the
individual and public health burden of this disabling and distressing clinical issue. The patient
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population was a crucial indicator in the development of the PICOT question. The outpatient
cancer center provides treatment for a high volume of breast cancer patients; thus, a convenience
sample for the QI project included patients from 20 to 80 years of age who were diagnosed with
breast cancer and developed lymphedema. Based on the review process, the PICOT question was
formulated as follows:
P: Patients ages 20 to 80 diagnosed with breast cancer who developed lymphedema.
I: Prophylactic Bioimpedance Spectroscopy for Breast Cancer-Related Lymphedema
C: Treatment of BCRL after diagnosis.
O: Reduction of chronic BCRL.
T: Six weeks.
Planning the Study of the Intervention
I adapted evidence-based practice in the clinical setting by utilizing a translational
framework provided by Lewin’s Organizational Theory of Change and the three-step change
model (1951) that includes Unfreezing, Change, and Refreezing. In collaboration with the
Medical Director and my collaborating physician, I identified a need for prophylactic use of BIS
for BCRL. The first step, or Unfreezing, involved a change in the methods used for detection and
treatment of lymphedema after diagnosis. The introduction of new technology prompted
disturbances to the organization's status quo. This disequilibrium was the driving force needed to
overcome resistance from stakeholders who questioned the clinical value of this QI. This
initiative permitted me to focus on strategic planning to strengthen the reinforcement of the
planned change. The Change step permits trial and error regarding the use of preventative BIS.
This procedure was performed during routine follow-up visits. Meanwhile, I observed decreased
levels of resistance to change among the various stakeholders involved (Refreeze). Evaluation of
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BIS evidence-based practice revealed the need to improve the services that I currently provide
for survivors of breast cancer. Early detection, diagnosis, intervention, and prevention while the
condition remains in a reversible state are key components of optimal BCRL management. BIS
can be performed before, during, or after breast cancer treatment and repeated every three
months or at regular intervals up to 36 months. While the organization will revert to the original
status quo if it fails to acknowledge the normality of new behavior (Manchester et al., 2014), the
ongoing availability of BIS, its reinforcement through routine use, and the recognition of its
important role in preventing BCRL will most likely lead to its sustained use in my clinical
setting.
The plans for assessing how well the intervention was implemented began with the
selection of a QI model. The Plan-Do-Study-Act (PDSA) cycle for evidence-based QI projects is
a four-stage problem-solving model that can be used for rapid improvement and/or carrying out
change (SlideModel, 2022) as follows:
Plan. I was the central provider during this stage. I completed the American Academy of
Nurse Practitioners National Certification Board for the State of Texas Professional and
Individual Scope of practice and generated a detailed 10-day reflective practice log covering
events that transpired over 10 working days. I reflected on every step of the advanced practice
and processes involved in caring for patients and reviewed areas for potential practice
improvement. A review of patients was generated and organized by diagnosis and treatment.
Insight was gained from my extensive review of the assessments, diagnoses, interventions, and
follow-ups. Three potential practice problems were organized into PICOT questions. The DNP
Chair approved the final PICOT question selected (see above), and a literature review was
initiated. A minimum of six publications with high-quality evidence (levels 9–12) supported the
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PICOT question. The publications presenting the three highest levels of evidence were wellsummarized and supported the PICOT question. The translational frameworks (Lewin’s
Organizational Theory of Change and QI Model PDSA Cycle Evidence-Based Practice QI) were
presented together with the anticipated outcome and local impact of the completed DNP QI
Project. The worksite supervisor signed the DNP QI Proposal and provided a signed work letter
on department letterhead. Once DNP Chair approval was received, an IRB QI application was
submitted. The IRB provided me with a letter that stated that this QI project did not come under
the auspices of human subjects research. I also reviewed my January 2022 schedule and
collected initial BIS measurements performed on breast cancer patients at risk for BCRL.
Do. This stage focused on the implementation of the project. Evidence-based educational
material was provided to potential candidates who met the criteria as outlined in the IRB
application. These materials motivated these patients to take an active role in their care. I
obtained baseline L-Dex measurements on each of these patients; the reference scores for this
value are -10 to +10. Patients with baseline scores ≥10 were diagnosed immediately with
subclinical (stage 0) lymphedema and provided with treatment. Patients with scores within the
reference range were asked to return in one week for follow-up testing. If no lymphedema was
detected at the one-week follow-up (i.e., L-Dex < 6.5 points over the original baseline), patients
were asked to return for another follow-up visit in four weeks. By contrast, patients with scores
that were ≥6.5 points over their original baseline were diagnosed with subclinical (stage 0)
lymphedema at that time. These patients were managed with a four-week at-home intervention
that included compression garments and referral for their appropriate fitting. All patients with
stage 0 lymphedema were also asked to return to the clinic in four weeks. If the L-Dex score at
follow-up was the same or higher, a referral for ongoing therapy was made (Shah et al., 2016).
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Secondary therapy may include outpatient lymphedema therapy with specialized therapists who
offer one-on-one expert care at several locations including The Hospitals of Providence,
University Medical Center, Paloma Wellness and Rehabilitation, and Manual Physical Therapy
Specialists. A post-treatment surveillance follow-up visit at three months was recommended for
all patients. An L-Dex score was documented together with vital signs.
Before undergoing a BIS examination, patients were asked to remove their socks and all
metal jewelry and devices. I confirmed that the patient was not pregnant and did not have any
implanted electronic devices. I also ascertained that we were not in the presence of a strong
electromagnetic field. Patients were then asked to lay in a supine position and both right and left
arms were examined. The arms remained uncrossed with legs apart to avoid short-circuiting the
electrical path. The skin was prepared to facilitate contact with the electrode and avoid
measurement inconsistencies by gently rubbing the contact sites with alcohol wipes to remove
excess oil. I applied the adhesive side of each electrode to the skin at placement sites that have
been standardized for unilateral arm measurements. Single dual-tab electrodes were placed on
the right hand, the left hand, and the right foot. I placed the proximal ends of two electrodes (one
on each hand) with the green line on the midline of the ulnar styloid process with the distal end
extending toward the fingers. I placed the proximal end of the third electrode with the green line
between the medial and lateral malleolus with the distal end extending toward the toes. I then
obtained a baseline measurement by confirming unilateral measurement parameters as shown on
the screen; three measurements are needed to calculate a single result. I then connected one lead
to each electrode via their attached alligator clips according to the color-coding displayed on the
BIS screen. After each measurement was performed, the device displayed the impedance on the
raw results screen. The results are displayed as black dots in a plot of resistance (R) versus
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reactance (X). A best-fit curve is calculated and displayed as a solid blue line within this graph.
High-quality data generate a semicircular pattern (ImpediMed, 2014).
Study: The results of this analysis in terms of the reduction of chronic BCRL as
determined by BIS were determined. I also evaluated what went wrong and/or what was learned.
The use of BIS led to improvements in the early detection of BCRL. For example, one patient
presented with a baseline measurement (L-Dex) of 15.8 and was diagnosed with subclinical
(stage 0) lymphedema at that time. The patient was diagnosed with a triple negative receptor left
breast cancer, stage 3A, who was undergoing neoadjuvant chemoimmunotherapy. A four-week
at-home intervention was implemented that included compression garments and a referral for
fitting; the patient was asked to return to the clinic in four weeks. The post intervention L-Dex
score were 3.8 and 3.3 on her left and right arms, respectively. This approach was worth the
investment as it facilitated earlier detection of BCRL on routine follow-up visits. I reported
specific positive trends in L-Dex scores. There were no unmanageable side effects. I also learned
that it was important to coordinate these efforts so that the patients did not need to schedule
appointments at two separate locations. The plan was overall a success.
Act: I plan to implement BIS as the standard of care for breast cancer patients at risk of
developing BCRL. I also recognize that there is always an opportunity for further improvement.
For example, our entire organization may need to be more focused on modern technology, as all
providers, researchers, educators, and staff can benefit from sustained and successful practice
change (Roush, et al., 2020). Improvements achieved and lessons learned as part of this QI
project are shared with others in our organization. I will be taking steps to sustain this QI by
bringing this to the attention of corporate management. My goal is to have BIS incorporated into
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routine care practice for the breast cancer community. My long-term plans for additional
improvement involve iterative PDSA cycles as needed.
Literature Review
Shah, et al. (2016) reported that the use of BIS facilitated earlier detection of BCRL with
increased sensitivity and supported surveillance screening for early intervention. A related metaanalysis concluded that BIS monitoring for early intervention significantly reduces the risk of
developing chronic BCRL, including 69% and 81% reductions when compared to control and
circumference measurement techniques, respectively. This was particularly evident in patients
who had undergone a mastectomy, ALND, regional node irradiation (RNI), or taxane-based
chemotherapy who are at an increased risk of developing BCRL. In these cases, BIS can aid in
the assessment of stage 0 lymphedema and trigger early intervention (Shah et al., 2021).
Bioimpedance-based measurement techniques can be used for clinical diagnosis by quantifying
the extent of abnormal fluid accumulation (Silva, et al., 2019). A randomized control trial (RCT)
compared tape measure (TM) and BIS measurements for BCRL surveillance screening of newly
diagnosed patients with the intent of identifying and treating subclinical BCRL to improve
patient outcomes. The results of this RCT included statistically significant results, leading the
authors to suggest that BIS screening might be used as a standard approach to BCRL
surveillance. BIS provides the benefits of precise identification and thus facilitates the early use
of compression therapy compared to the conventional TM approach (Ridner, et al., 2022). BIS is
considered a reliable and sensitive modality that can be used to detect early changes in interstitial
fluid (O’Toole et al., 2013). A secondary analysis of a randomized parent study in which patients
were followed for 24 months with frequent BIS assessments during the 15-month post-surgical
period revealed statistically significant L-Dex scores leading to early detection of stage 0
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lymphedema (Ridner, et al., 2020). Similarly, Boyages et al., (2021) published the results of an
RCT that compared the risk of developing subclinical BCRL in patients treated with ALND and
RNI as detected by BIS and TM methods. The use of BIS resulted in superior detection of
subclinical BCRL compared to TM, thus supporting its use in post-treatment surveillance aimed
at early detection and intervention.
BIS can be used for early detection and intervention as L-Dex scores ≥6.5 above baseline
clearly indicate subclinical (stage 0) lymphedema that can be managed with a four-week at-home
intervention and follow-up. Plans were made to evaluate the effectiveness of this change by
arranging for repeated tests at regular intervals with routine follow-up visits as standard practice.
Evidence-based guidelines from the National Lymphedema Network suggest the value of
BIS-based diagnostic therapeutics for the early detection of BCRL (Shah, et al., 2016). RCT,
systematic reviews, meta-analysis, randomized prospective trials, secondary assessments of a
randomized parent study, and NCCN guidelines support the collection of bilateral pretreatment
values as baseline measurements. The effects of the intervention were evaluated based on L-Dex
scores obtained at the initial and first follow-up (i.e., one-week post-baseline measurements) as
well as at four-week post-intervention follow-up visits. Instruments that have been identified as
valid and reliable include BIS, water volumetry, TM, and perometry. Of these, BIS can detect
alterations in the extracellular fluid (ECF) in stage 1 lymphedema which supports established
internal validity. A systematic review and meta-analysis focused on the external validity of this
modality for the detection of unilateral arm lymphedema after breast cancer indicated a clear
need for improved understanding of contributing risk factors, prevention, and management
strategies that can be used to reduce the individual and public health burden of this disabling and
distressing clinical problem (Disipio, et al., 2013).
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Methods of Evaluation
Data collection began on January 18, 2022, and ended on March 2, 2022. Chart reviews
were conducted and the screening process of breast cancer patients at risk for developing BCRL
was initiated. As part of this screening process, I considered gender, age, stage of disease,
diagnosis, and treatment type. One hundred and thirty-one charts were reviewed, and five
participants were included in the QI project. Baseline measurements were obtained using BIS.
Instruments and procedures used to assess the effectiveness of implementation, contributions of
the intervention, and anticipated outcomes were outlined in the IRB application. After
performing baseline measurements, patients were asked to return to the clinic in one week for a
second assessment. At this visit, patients with a change in L-Dex score ≥6.5 were provided with
a four-week at-home intervention that included the use of compression garments; a referral for
fitting was also provided. Patients undergoing this at-home intervention were asked to return four
weeks later for a follow-up assessment. Of note, patient #3 presented with a baseline score of
15.8, which suggested subclinical lymphedema; an intervention was made at that time. This
patient was then asked to return in four weeks for a follow-up assessment.
Three measurements are required to calculate a result. After each measurement, the
device displayed the measured impedance in the raw results screen. The L-Dex score includes
measured bioimpedance parameters over a range of frequencies (4–1000 kHz) and results in 256
data points. These bioelectrical parameters are then used to determine the L-Dex score for the atrisk limb. These values can be compared to those obtained for the unaffected limb. Unilateral LDex scores >10 and scores ≥6.5 over baseline values were considered as early signs of
lymphedema. The screen device also permits the operator to view previous results to determine
whether L-Dex scores are increasing or decreasing over time. The results are displayed as black
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dots in a plot of resistance (R) versus reactance (X). Best fit curves are calculated from these data
points and displayed as a solid blue line. High-quality data results in a semicircular pattern. BIS
is a valid and reliable technique that is four times more sensitive at detecting BCRL than any
other commonly used modality (ImpediMed, 2014).
Analysis
BIS analysis was performed on five patients. The impedance data shown in the raw
results screen was reviewed to ascertain the quality and validity of each measurement. The final
results (measured in Ohms) are shown as black dots in a plot of resistance (R) versus reactance
(X). A semi-circular best fit curve was calculated for each measurement confirming the
collection of high-quality data. These results were used to calculate L-Dex scores based on the
ratio of the impedance determined for the at-risk limb versus the uninvolved limb. Figure 1 is an
example of BIS data presented as a reactance versus resistance curve (ImpediMed Oncology,
2021).
Figure 1
Results of Bioimpedance Spectroscopy
Raw Results Impedance, Resistance, Reactance
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The average baseline L-Dex score for the five patients enrolled in my QI project was 5.98. The
average L-Dex score for the four patients seen at one-week follow-up was 3.3. The average LDex score on the second follow-up visit was 3.4. BIS measurements at baseline as well as at oneweek and five-week follow-up visits for all participants are shown in Figure 2.

Results
A rigorous review of the literature provided evidence that supported the clinical QI
project in which BIS would be used for early detection and ongoing monitoring for BCRL. This
methodology was used to improve the detection of subclinical (stage 0) lymphedema and thus to
reduce the risk of developing chronic BCRL (Shah et al., 2021). The project was performed at an
outpatient cancer treatment center located in central El Paso, Texas. Physical resources were
readily available to support this QI. This center is part of a for-profit company with an
established organizational hierarchy, philosophy, values, and expectations. Historically, efforts to
promote change have been predominantly research-based. Structures and patterns of care that
provided context for this BIS intervention for five patients at risk for developing BCRL adhered
to the standards of practice for the state of Texas and the American Academy of Nurse
Practitioners National Board Certification regulatory boards. The results of the intervention are
discussed in the paragraphs that follow.
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Figure 2
Bioimpedance Spectroscopy Measurements for each participant

Patient #1
Patient #1 who was first seen on January 18, 2022, is a 48-year-old female who
underwent a left breast lumpectomy and SLNB. Her ALND was negative (4/4 lymph nodes). Her
tumor was hormone-receptor-positive with a low Oncotype Dx score, indicating a <1%
likelihood of benefitting from chemotherapy. She began adjuvant radiation therapy on March 2,
2022; once this has been completed, she will be treated with adjuvant hormonal therapy. The
baseline L-Dex scores were 3.8 and 3.5 on her left and right arms, respectively. She returned to
the clinic one week later (January 26, 2022) for a follow-up assessment post-surgery. At this
time, her L-Dex scores were 3.4 (left arm) and 3.3 (right arm). At her four-week follow-up visit
on February 23, 2022, her L-Dex scores were 3.5 (left arm) and 3.6 (right arm). No lymphedema
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was detected either visually or objectively based on the L-Dex data. She will remain on posttreatment surveillance. Final determination: outcomes met.
Patient #2
Patient #2 was seen on January 24, 2022, while undergoing cycle 8 of taxane-based
chemotherapy. She is a 70-year-old female who was status post a left breast lumpectomy and
SLNB. Her ALND was positive (9/16 lymph nodes) which is associated with a high risk (>30%)
of distant recurrence. She began adjuvant radiation therapy on March 17, 2022, followed by
treatment with a hormonal blocking agent. Baseline lymphedema measurements (L-Dex scores)
while on active taxane-based chemotherapy were 3.5 and 3.5 in her left and right arm,
respectively. She returned to the clinic one week later on January 31, 2022, for a follow-up
assessment. At that time, her L-Dex scores remained unchanged. She presented for a follow-up
visit four weeks later on March 2, 2022, upon completion of chemotherapy; her L-Dex scores at
that time were 3.5 (left arm) and 3.4 (right arm). No lymphedema was detected either visually or
objectively based on the L-Dex data. She will remain on post-treatment surveillance. Final
determination: outcomes met.
Patient #3
This patient was first seen on January 24, 2022. She is a 67-year-old female who
presented at this time for a treatment review and coordination visit to address pretreatment and
surgery. She had been previously diagnosed with aggressive triple-negative cancer of the left
breast and had undergone neoadjuvant chemotherapy to shrink the tumor. Chemoimmunotherapy
was scheduled to begin on February 18, 2022. Baseline BIS measurements taken at this time
revealed L-Dex scores of 15.8 in the left arm and 15.6 in the right arm. She was managed with a
four-week-at-home intervention using compression garments; a referral for fitting was made at
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this visit. BIS measurements performed four weeks later March 2, 2022, revealed L-Dex scores
of 3.8 and 3.3 in the left and right arms, respectively. No lymphedema was detected based on
observation, vital signs, and objective data. She will remain on post-treatment surveillance. Final
determination: outcomes met.
Patient #4
Patient #4 was a 63-year-old female who had undergone a left breast lumpectomy with
ALND. She was first seen on January 26, 2022, after the completion of adjuvant radiation and
was followed by adjuvant hormonal therapy. Her history was notable for a low Oncotype Dx
score indicating a <1% likelihood of benefitting from chemotherapy. Her baseline BIS
measurements on January 26, 22 were 3.7 (left arm) and 3.7 (right arm). She returned to the
clinic one week later for a first follow-up assessment; her L-Dex scores at that time were 3.3 and
3.0 (left and right arms, respectively). She returned to the clinic on March 2, 2022, for a fourweek follow-up visit. Her L-Dex scores at this visit were 3.5 (left arm) and 3.5 (right arm). No
lymphedema was detected based on objective data. She will remain on post-treatment
surveillance. Final determination: outcomes met.
Patient #5
Patient #5 was seen in the office on January 26, 2022, for treatment review and
coordination. She was a 62-year-old female diagnosed with hormone-receptor-positive breast
cancer who was on neoadjuvant dose-dense taxane-based chemotherapy to shrink the tumor for a
better surgical outcome. Her baseline pre-chemotherapy L-Dex scores were 3.6 and 3.3 in her
left and right arms, respectively. She returned to the clinic one week later on February 2, 2022,
for a follow-up assessment. Her L-Dex scores at that time were 3.6 and 3.6 (left arm and right
arm, respectively). She returned to the clinic on March 2, 2022, after two cycles of
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chemotherapy. Her L-Dex scores at that time were 3.4 (left arm) and 3.6 (right arm). No
lymphedema was documented with objective data. She will remain on post-treatment
surveillance. Final determination: outcomes met.
The initial plan evolved over time. Nonetheless, our findings suggest that BIS was highly
effective when used for the early detection, management, and treatment of BCRL. Current data
support surveillance screening for early detection and management of BCRL; sensitive
diagnostic modalities such as BIS are more effective at detecting subclinical BCRL compared to
traditional techniques, thereby facilitating early intervention (Shah et al., 2016). Results from
published RCT studies suggest that BIS screening should be standard of care for BCRL
surveillance. The use of this technique facilitates precise detection of this complication and
identifies patients who are likely to benefit from compression therapy (Ridner et al., 2022).
Unfortunately, one RCT focused on the detection of BCRL by arm circumference measurements
both with and without BIS in patients with stage I–III breast cancer was terminated due to the
departure of the Principal Investigator (Clinical Trials, 2018).
Discussion
Summary
The results of my study suggest that BIS is a practical and cost-effective method that can
be used to diagnose secondary lymphedema that develops in response to the treatment of
neoplastic disease. BIS can provide measurements of extracellular volumes within individual
body segments that may develop lymphedema. This test can be performed both before and after
treatment and can provide a quantitative assessment of the degree of fluid accumulation (Silva et
al., 2019). The results of an RCT that focused on the risk of developing subclinical BCRL based
on the extent of the ALND, SLNB, and in patients who have or have not undergone radiation
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therapy concluded that BIS provided superior post-treatment surveillance and was more effective
at detecting subclinical lymphedema (Boyages et al., 2020). Breast cancer patients who
underwent surgery or radiation to the axillary, supraclavicular, or cervical regions are at
increased risk for the development of lymphedema. Baseline pretreatment measurements of both
limbs can be performed at regular intervals as part of routine follow-up visits to facilitate early
detection and diagnosis for optimal lymphedema management. Of note, while stage 0 and stage 1
BCRL are reversible, stages 2 and 3 are less responsive to treatment and typically irreversible
(National Comprehensive Cancer Network, 2021). My findings suggest that BIS can be
introduced as a standardized interventional approach for early detection and management to
reduce the incidence of chronic BCRL. All five patients who were managed with BIS had
positive outcomes. Patient #3 had the most dramatic response to this approach. This patient
presented with baseline L-Dex scores of 15.8 and 15.6 (left and right arm, respectively), which
suggested subclinical (stage 0) lymphedema. The patient was managed with a four-week at-home
intervention using compression garments. Follow-up L-Dex scores were 3.8 (left arm) and 3.3
(right arm) were within the normal range of values, suggesting dramatic improvement. The
patient presented no additional difficulties and has been scheduled for post-treatment
surveillance (Texas Breast Specialist, 2020). Thus, the overall goal of this project has been met,
as the QI project has identified a clear benefit for a specific breast cancer population.
Relation to Other Evidence
I identified substantial literature supporting early intervention and treatment of BCRL.
The most significant benefit results from an approach involving monitoring of high-risk patients,
including those who have undergone ALND, RNI, and taxane-based chemotherapy (Shah et al.,
2016). Shah et al., (2016) published the results of two randomized trials focused on the outcomes
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of early intervention with physiotherapy, exercise, and manual lymphatic drainage; however,
both studies were small with a very short follow-up period. Shah et al., (2020) also published a
meta-analysis study that compared BIS to arm circumference measurements and reported that
patients monitored with BIS were significantly less likely to develop BCRL when compared to
background rate (i.e., no monitoring) or monitoring with the TM method. The results also
suggested that BIS monitoring was associated with reductions in the annual incidence of BCRL
in high-risk populations (i.e., 40% post-mastectomy and 50% post-ALND).
Early detection can be used to identify patients who might benefit from early
interventions such as compression garments, thereby preventing the development of chronic
BCRL. There is substantial evidence in the literature indicating that active monitoring of BCRL
significantly reduces the likelihood of progression to chronic BCRL (Shah et al., 2021). One
recent systematic review reported that bioimpedance-based techniques could be used to detect
extracellular fluid volumes both before and after treatment. Furthermore, a report that used the
Cochrane tool identified seventy-five studies with a high risk of bias and two studies with
uncertain risk. The domains with the highest risk of bias were those related to the size of the
study cohort which did not result in security regarding the statistical evaluation. Nonetheless,
despite these issues, the authors of this systematic review concluded that BIS was a valid and
effective modality that could be used to evaluate the composition of interstitial volumes both
before and after treatment and to direct clinical follow-up of patients at risk for developing
lymphedema (Silva et al., 2019). Results from another study provided data suggesting the need
for long-term (24 months) surveillance with frequent assessments every three months up to 15
months postoperatively. Ridner et al. (2020) reported that BIS was beneficial for the early
identification of subclinical lymphedema based on statistically significant L-Dex scores. Further
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studies will be needed to obtain insight into contributing risk factors and the optimal prevention
and management strategies that might be used to reduce the individual and public health burden
associated with this disabling complication (DiSipio et al., 2013). Similarly, Bundred et al.,
(2015) reported a modest correlation in a study in which multi-frequency bioimpedance was
compared with perometry for the early detection of BCRL post-axillary node clearance (ANC)
and suggested that further study of these modalities was needed.
Limitations
Limited investment in modern technology can limit the number of BIS screenings
available to patients compared to current technology; in this case, the use of BIS may be more
cumbersome and less cost-effective. However, the number of participants will most likely
increase if BIS screening becomes standard of care. The reinforcement of preventative BIS use
and the observed reduction in the number of patients who develop chronic BCRL will most
likely increase the sustainability of this new practice unless the organization fails to acknowledge
and normalize this new behavior. Efforts to minimize study limitations include improving
practice fidelity with evidence-based practice and the introduction of BIS. The effect of
constraints on the interpretation and application of BIS-based interventions prompted
disturbances to the status quo of our current practice. However, there remains a driving force
directed at overcoming resistance from stakeholders, providers, educators, and researchers who
question the clinical value of this QI effort.
Interpretation
Efforts to address the possible reasons for differences between anticipated and observed
outcomes begin with a comparison of research-focused expectations as opposed to those that
result in practice-focused clinical settings. While research-focused results rely on the
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interpretation of carefully controlled studies, a practice focus reports the results of real-world
outcomes. Translation of research-focused evidence into nursing and healthcare practice can be
challenging. Interprofessional collaboration is imperative if one hopes to promote the
sustainability of a given practice change. Modifications directed at improving future performance
are among the ways to acknowledge the normality of any new behavior. The impact of early
detection is one of the driving factors promoting the increased use of BCRL screening. Recent
guidelines that support early detection and intervention have focused on subclinical (stage 0)
lymphedema; detection of this complication at this reversible stage can result in a reduction in
rates of chronic BCRL. BIS is a valuable, practical, and cost-effective screening tool that can be
used for early detection of BCRL and will help to prevent and manage the devastating effects of
this potentially chronic disability (Kaufman et al., 2017).
Conclusions
Lymphedema is a disabling condition and a major post-surgical complication experienced
by breast cancer patients. BCRL is one of the most feared consequences of survivorship as it
serves as a constant reminder of their cancer diagnosis and its treatment (Dean et al., 2018).
Chronic lymphedema is preventable if it is caught early on in its development. The use of BIS
presents an opportunity for detection, intervention, and reversal of this disabling condition before
the onset of fibrosis (Mayrovitz et al., 2009). BIS provides caregivers with an L-Dex score that
can be used for the reliable diagnosis of subclinical (stage 0) lymphedema. The L-Dex score is a
validated metric for lymphedema detection; a baseline score >10 or an increase ≥ 6.5 over a
baseline value indicates the need for clinical intervention. Evidence-based clinical diagnostic
outcomes from BIS are superior to those provided by commonly used conventional
methodologies. Current evidence supports the use of BIS as a standardized clinical approach as it
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has sufficient sensitivity and specificity to detect subclinical lymphedema (Dylke et al., 2016).
Many nurses are undertaking QI projects that will have an impact on the clinical and financial
operations of their organizations. BCRL is a profoundly important clinical issue with a
tremendous impact on cancer survivors. Implementation of preventative strategies using BIS will
ultimately reduce the cost of care, provide early recognition and prevention of chronic BCRL,
decrease hospital length of stay, and improve care coordination and critical patient outcomes.
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